Aug. 10, 2012News & Opinions
AstraZeneca has opted to pay a further $135 million to Bristol-Myers Squibb to get an equal say in decision-making regarding drugs developed by Amylin Pharmaceuticals, the diabetes specialist acquired jointly by the two partners.
Aug. 03, 2012News & Opinions
Global biotech merger volume has reached levels not seen in four years as big pharmaceutical companies pursue deals to get access to new drugs, with bankers saying therapeutic areas such as cancer, inflammation and autoimmune diseases are ...
Aug. 02, 2012News & Opinions
A Bristol-Myers Squibb executive has been criminally charged with insider trading, accused of buying options in three companies that the drugmaker was looking to buy.
Jul. 21, 2012News & Opinions
Aggressive consolidation among U.S. and European generic drugmakers is putting pressure on smaller competitors in the industry, whose best hope of surviving a brewing price war may lie in finding specialised niches.
Jul. 18, 2012News & Opinions
Large investors in U.S. biotech companies are likely to capture serious windfall profits as deal activity picks up in the sector.
Jul. 13, 2012News & Opinions
Annual global spending on prescription drugs will rise 25% by 2016 to $1.2 trillion, as surging growth in emerging markets eclipses weak gains in developed markets like the United States, according to healthcare information provider IMS ...
Jul. 12, 2012News & Opinions
AstraZeneca has clinched two new deals in neuroscience, underlining the drugmaker's increasing reliance on external projects to refill a sparse pipeline as it tests a new low-cost approach to drug research.
Jun. 30, 2012News & Opinions
Simon Lowth may only be the interim chief executive of AstraZeneca but he is ready to sign off on bold deals.
Jun. 02, 2012News & Opinions
AstraZeneca and Bristol-Myers Squibb are among several pharmaceutical giants that have submitted initial bids for Amylin Pharmaceuticals, the diabetes drugmaker that is exploring a sale, according to people familiar with the matter.
Apr. 27, 2012News & Opinions
U.S. drugmaker Bristol-Myers Squibb said on Thursday that it received a subpoena from securities regulators regarding its sales and marketing practices in various foreign countries.
The latest information directly via newsletter.